Effects of Brain Beta-Amyloid on Postoperative Cognition

StatusActive, Not Recruiting
PhasePhase 4
Started

Record status This record was last updated May 1, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jun 2023 to Jun 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 66
    • Site details revised
    v14
  2. Primary and study completion dates: Jun 2022 to Jun 2023v13
  3. Re-verified, no change to tracked fieldsv12
  4. Primary and study completion dates: Jun 2020 to Jun 2022v11
  5. Primary and study completion dates: Jun 2019 to Jun 2020v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary and study completion dates: Jun 2018 to Jun 2019v9
  2. Primary and study completion dates: Jun 2017 to Jun 2018v8
  3. Primary and study completion dates: Jun 2016 to Jun 2017v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary and study completion dates: Apr 2015 to Jun 2016v5
  6. Re-verified, no change to tracked fieldsv4
  7. Enrollment target: 65 to 100
    • Primary and study completion dates: Apr 2014 to Apr 2015
    • Interventions: Florbetapir F 18 (18F-AV-45) (Drug) to Florbetapir F 18 (18F-AV-45) (Drug), no intervention (Other)
    • Study arms: 0 to 2
    v3
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Postoperative cognitive decline (POCD) affects up to 50% of non-cardiac surgical patients greater than or equal to 65 years of age. This study will test the hypothesis that preoperative presence of brain beta-amyloid plaques in non-demented subjects increases postoperative cognitive decline (POCD) in elderly subjects scheduled for hip or knee replacement. The investigators hypothesize that preoperative beta-amyloid plaques will predict postoperative cognitive decline.
Trial Details
NCT Number NCT01606488
Lead Sponsor University of California, San Francisco
Collaborators: Alzheimer's Drug Discovery Foundation, Avid Radiopharmaceuticals
Conditions
(from sponsor)		 Postoperative Cognitive Dysfunction
Related terms Alzheimer Disease, Postoperative Cognitive Complications
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov